GSK signs ‘bubble boy disease’ agreement with MolMed

GlaxoSmithKline’s efforts to tackle a rare and often deadly immune deficiency are making progress following the announcement that they have signed a deal with Italy’s MolMed. In October last year, GSK linked up with San Raffaele Telethon Institute, gaining an exclusive licence to an investigational gene therapy for ADA-SCID (adenosine deaminase deficiency – severe combined

Continue Reading